Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 studyEzra E.W. Cohen, Signe Friesland, Denis Soulières et al.|The Lancet|2018Cited by 1.7k
Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12Christopher Garris, Mikaël J. Pittet, Sean P. Arlauckas et al.|Immunity|2018Cited by 937
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trialGeorgina V. Long, Dirk Schadendorf, Uwe Trefzer et al.|The Lancet Oncology|2012Cited by 906
Pembrolizumab Cutaneous Adverse Events and Their Association With Disease ProgressionMartina Sanlorenzo, Susana Ortiz‐Urda, Adil Daud et al.|JAMA Dermatology|2015Cited by 452
Dynamic CD8+ T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodesMaha K. Rahim, Matthew H. Spitzer, Trine Line Hauge Okholm et al.|Cell|2023Cited by 410